Pieris Pharmaceuticals Inc (NAS:PIRS)
$ 10.1 -0.24 (-2.34%) Market Cap: 13.33 Mil Enterprise Value: -12.83 Mil PE Ratio: 0 PB Ratio: 0.56 GF Score: 46/100

Pieris Pharmaceuticals, Inc. - Special Call Transcript

Nov 19, 2019 / 05:30PM GMT
Release Date Price: $303.2
Stephen S. Yoder
Pieris Pharmaceuticals, Inc. - CEO, President & Director

(technical difficulty)

Joining me from the Pieris side upfront are Ingmar Bruns, MD, PhD, our Head of Clinical Development; and then 2 seats down, Shane Olwill, PhD, our Head of Translational Science. I'll get to the other colleagues, guest speakers in just a moment.

And I wanted to mention at the outset that Ingmar and Shane will be joining me in introducing our guest speakers. They'll be adding Pieris'-specific content. And also, they'll be facilitating our Q&A in the oncology and respiratory sections. And in the context of this, we may be making forward-looking statements, so I would ask you to consult our disclaimer found on Slide #3.

Pieris is a company that is deploying a single class of next-generation therapeutic proteins that we call Anticalins, and we're deploying them to create 2 different franchises.

On one side, we are constructing and developing bivalent bispecifics with the objective of an agonizing tumor-specific T cells in the tumor microenvironment by agonizing

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot